AlphAIAlphAI — Financial news for AI agents
stockstotrade.com$GKOS

Glaukos (GKOS) Jumps As iDose TR Data And Retinal Deal Fuel Bullish Setup

Glaukos (GKOS) stock rose 11.67% on October 28, 2026, driven by positive Phase 4 data for iDose TR and a retinal deal with RevOpsis. The company reported strong results for its corneal therapy Epioxa and secured exclusive rights to retinal biologics. Analysts raised price targets, with BTIG setting it at $205 and Mizuho at $190. GKOS trades at 16x sales with negative margins, focusing on growth potential. Upcoming Q3 earnings on October 28, 2026, are a key catalyst.

Original reporting
stockstotrade.com
Published Oct 28, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 3:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Glaukos (GKOS) Jumps As iDose TR Data And Retinal Deal Fuel Bullish Setup — source image
Source · stockstotrade.com
Decision brief

The 30-second read

$GKOSBullishHigh
01

Why it matters

The new data de‑risks the product pipeline and expands market addressable size, likely attracting short‑term buying pressure.

02

Market read

First‑time disclosure of late‑stage trial results and a strategic partnership creates a high‑impact catalyst for GKOS and may influence related medtech stocks.

03

What to watch

Potential reimbursement challenges and competition from larger pharma in retinal space could temper upside.

Relevance 8/10Novelty 8/10Timing: after‑hours reaction

Background

Glaukos (GKOS) reported Phase 4 trial success for iDose TR and announced a global license for a novel retinal biologic, prompting a sharp price move.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Phase 4 iDose TR data met primary endpoints and a new global retinal license deal were disclosed for the first time, driving an 11.7% intraday jump.

Expected impact

likely upward as market absorbs strong trial results and retinal deal

Evidence & confidence

First‑time disclosure of Phase 4 data and a strategic licensing agreement provides fresh, material information that can move the stock in the short term.

Market effects

Sector

Boosts outlook for the ophthalmology/medtech sector as successful late‑stage data may raise peer valuations.

Regional

Positive for US biotech equities, especially small‑cap growth medtech names.

Global

Highlights growing interest in retinal therapeutics, potentially influencing global biotech funding trends.

Counterpoint

What could challenge this read

The stock remains highly volatile with negative margins; a pullback could occur if adoption lags.

Key entities

  • company
    Glaukos Corporation

    US‑listed ophthalmology device maker reporting trial data and a retinal deal.

  • company
    RevOpsis Therapeutics

    Partner providing the RO‑104 retinal biologic licensed to Glaukos.

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

4 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com